An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg.

Trial Profile

An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Cancer; Rheumatoid arthritis; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Oct 2015 Results published in the Clinical Therapeutics
    • 15 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 15 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top